Part I: Global TB SNAPSHOTS
1. China (Asia: Category 3)
2. India (Asia: Category 4, also including Pakistan, Afghanistan, all SE Asia except Cambodia and Burma)
3. Cambodia (Asia: Category 5, also including Burma, North Korea)
4. Japan (Asia: Category 1) 5. Egypt (Africa: Category 1, also including Libya, Tunisia, Western Sahara)
6. Algeria (Africa: Category 3)
7. Tanzania (Africa: Category 4, also including Angola, Sudan, Chad...)
8. South Africa (Africa: Category 5, also including all sub-Sahara Africa except Tanzania and Angola)
9. Mexico (North America: Category 1, also including US and Canada)
10. Brazil (America: Category 2)
11. Honduras (America: Category 3)
12. Peru (America: Category 4)
13. Iran (Mideast: Category 1)
14. Turkey (Europe: Category 2)
15. Russia （East Europe: Category 4)
16. USA
17. Botswana （Africa 5)
18. Cuba (America 1)
19. Hong Kong (Asia 3)
20. Indonesia (Asia 4)
21. Nigeria (Africa 5)
22. Philippines (Asia 4)
23. Senegal （Africa 4）
24. Syria （Mideast 1）
Part II: Diagnosis, Treatment, and Treatment Management
25. Clinical diagnosis of TB: history, current practices, usefulness, defectiveness, and urgent need for new tools
26. Current treatment options: history, current practices, effectiveness, limitations, cost of the medicine, access to the medicine, common supplier of the medicine, various market and government supplies, public health services for DOT, and the urgent need for improvement
27. A case study: an historic review of DOT in China and future projections
28. Drug resistant TB; various causes of treatment failures, identification of drug resistant TB, prognosis and care for drug resistant TB patients, spread and increase of drug resistant TB, threats of drug resistant TB epidemics, future worst and best case scenarios, and the urgent need for new treatment medicines.
29. A case study: dealing with multiple drug resistant TB in China: current practices and future management strategies
30. Treating TB with HIV co-infections and other immune deficiency diseases: difficulties in detecting TB in HIV infected populations, increasing treatment problems associated with ARV treatment with TB co-infections, active TB resulting from organ transplant and other immune suppression, and etc.
31. A case study: major complications and concomitant disease, Surgery and operative indications, Bronchoscopy and stent, Intensive Care and Rescue of critical illnesses. 32. New TB diagnosis tool for early detection
33. New TB treatment medicine research and development
34. A case study: the history and future projection of clinical comparative testing of various TB medical treatment options in China
Part III: Prevention
35.
About the Author:
Yichen Lu, President, Haikou VTI Biological Institute
Hongjin Duanmu, President of Chinese National Tuberculosis Control and Prevention Society, Beijing Tuberculosis and Thoracic Tumor Research Institute
Lixia Wang, Director of National Center for TB Control and Prevention, Chinese National Center for Disease Control and Prevention
Chris Chanyasulkit, Director of TB Research Program, Haikou VTI Biological Institute
